OncoMatch/Lung Cancer — Non-Small Cell (NSCLC)/MET
Lung Cancer — Non-Small Cell (NSCLC)MET Clinical Trials
MET exon 14 skipping mutations occur in 3–4% of NSCLC and define a distinct genomic subset, more common in older patients and pulmonary sarcomatoid carcinoma. Capmatinib and tepotinib are FDA-approved for MET exon 14-positive NSCLC. Trials investigate MET amplification-driven disease, novel MET inhibitors, and combination strategies to address on-target resistance.
Top recruiting MET Lung Cancer — Non-Small Cell (NSCLC) trials
Ranked by phase and US site count.
See all trials matched to your profile →A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie
A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs
Shanghai JMT-Bio Inc.
A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive
Beijing Pearl Biotechnology Limited Liability Company
A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)
Beijing Pearl Biotechnology Limited Liability Company
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
Intergroupe Francophone de Cancerologie Thoracique